WO2001072322A3 - Administration parenterale de fortes doses de lactoferrine - Google Patents

Administration parenterale de fortes doses de lactoferrine Download PDF

Info

Publication number
WO2001072322A3
WO2001072322A3 PCT/NL2001/000253 NL0100253W WO0172322A3 WO 2001072322 A3 WO2001072322 A3 WO 2001072322A3 NL 0100253 W NL0100253 W NL 0100253W WO 0172322 A3 WO0172322 A3 WO 0172322A3
Authority
WO
WIPO (PCT)
Prior art keywords
lactoferrin
parenteral administration
high dosage
dosage parenteral
high dosages
Prior art date
Application number
PCT/NL2001/000253
Other languages
English (en)
Other versions
WO2001072322A2 (fr
Inventor
Bree Johannes Bernardus Ma Van
Johannes Henricus Nuijens
Original Assignee
Pharming Intellectual Pty Bv
Bree Johannes Bernardus Mathia
Johannes Henricus Nuijens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Pty Bv, Bree Johannes Bernardus Mathia, Johannes Henricus Nuijens filed Critical Pharming Intellectual Pty Bv
Priority to AU44865/01A priority Critical patent/AU4486501A/en
Publication of WO2001072322A2 publication Critical patent/WO2001072322A2/fr
Publication of WO2001072322A3 publication Critical patent/WO2001072322A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes de traitement utilisant de fortes doses de lactoferrine. La lactoferrine peut être administrée à fortes doses par voie parentérale sans effets secondaires importants pour traiter diverses affections, notamment des maladies infectieuses et l'inflammation.
PCT/NL2001/000253 2000-03-27 2001-03-27 Administration parenterale de fortes doses de lactoferrine WO2001072322A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44865/01A AU4486501A (en) 2000-03-27 2001-03-27 High dosage parenteral administration of lactoferrin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19335200P 2000-03-27 2000-03-27
EP00201110 2000-03-27
EP00201110.4 2000-03-27
US60/193,352 2000-03-27

Publications (2)

Publication Number Publication Date
WO2001072322A2 WO2001072322A2 (fr) 2001-10-04
WO2001072322A3 true WO2001072322A3 (fr) 2002-03-21

Family

ID=26072048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2001/000253 WO2001072322A2 (fr) 2000-03-27 2001-03-27 Administration parenterale de fortes doses de lactoferrine

Country Status (2)

Country Link
AU (1) AU4486501A (fr)
WO (1) WO2001072322A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2002077239A1 (ja) * 2001-03-27 2004-07-15 住友製薬株式会社 Ｈｃｖ結合性ポリペプチド
EP1360961A1 (fr) * 2002-05-07 2003-11-12 AM-Pharma B.V. Utilisation de peptides antibiotiques pour potentialiser l'activité des agents antimicrobiens
AU2003296447A1 (en) 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2004089986A1 (fr) * 2003-04-14 2004-10-21 Stichting Voor De Technische Wetenschappen Peptide antimicrobien de la famille des transferrines
US7034126B2 (en) 2003-05-14 2006-04-25 Agennix, Inc. Lactoferrin in the treatment of diabetes mellitus
CN1852728A (zh) * 2003-07-16 2006-10-25 纽约州州立大学研究基金会 宿主防御因子x(hdfx)
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
ITMI20052351A1 (it) * 2005-12-09 2007-06-10 Microbo Srl Nuovo uso farmaceutico delle transferrine e composizioni farmaceutiche derivate
WO2007100555A2 (fr) * 2006-02-21 2007-09-07 Ventria Bioscience Compositions contenant de la lactoferrine et leurs procédés d'utilisation pour favoriser la croissance de cellules cutanées
CN107304424B (zh) 2016-05-23 2019-05-10 成都福际生物技术有限公司 改造的转铁蛋白dna结合域、重组dna聚合酶及制备方法
EP3815707A4 (fr) * 2018-06-26 2022-04-06 S&K Biopharma, Inc. Inhibiteur et promoteur de glycosaminoglycane
IT202000005011A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso orale ad azione antivirale

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07291874A (ja) * 1994-04-22 1995-11-07 Morinaga Milk Ind Co Ltd ヘパリン中和剤
WO1995030339A1 (fr) * 1994-05-05 1995-11-16 Ferrodynamics, Inc. Clonage, expression et utilisations de la lactoferrine humaine
JPH0873499A (ja) * 1994-09-01 1996-03-19 Snow Brand Milk Prod Co Ltd 新規ペプチドおよび免疫賦活剤
WO1998033509A2 (fr) * 1997-02-03 1998-08-06 Pharming Intellectual Property Bv Proprietes utiles de la lactoferrine humaine et de variants de celle-ci
WO1999014231A2 (fr) * 1997-09-16 1999-03-25 Forssmann Wolf Georg Peptides bifidigenes
WO2001034641A2 (fr) * 1999-11-11 2001-05-17 Am-Pharma B.V. Activite antimicrobienne du premier groupe cationique de la lactoferrine humaine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07291874A (ja) * 1994-04-22 1995-11-07 Morinaga Milk Ind Co Ltd ヘパリン中和剤
WO1995030339A1 (fr) * 1994-05-05 1995-11-16 Ferrodynamics, Inc. Clonage, expression et utilisations de la lactoferrine humaine
JPH0873499A (ja) * 1994-09-01 1996-03-19 Snow Brand Milk Prod Co Ltd 新規ペプチドおよび免疫賦活剤
WO1998033509A2 (fr) * 1997-02-03 1998-08-06 Pharming Intellectual Property Bv Proprietes utiles de la lactoferrine humaine et de variants de celle-ci
WO1999014231A2 (fr) * 1997-09-16 1999-03-25 Forssmann Wolf Georg Peptides bifidigenes
WO2001034641A2 (fr) * 1999-11-11 2001-05-17 Am-Pharma B.V. Activite antimicrobienne du premier groupe cationique de la lactoferrine humaine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199602, Derwent World Patents Index; Class B04, AN 1996-017144, XP002178978 *
DATABASE WPI Section Ch Week 199621, Derwent World Patents Index; Class B04, AN 1996-205535, XP002178977 *

Also Published As

Publication number Publication date
AU4486501A (en) 2001-10-08
WO2001072322A2 (fr) 2001-10-04

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
MY136927A (en) Highly purified ethyl epa and other epa derivatives for neurological disorders
WO2001072322A3 (fr) Administration parenterale de fortes doses de lactoferrine
WO2002058620A3 (fr) Compositions pharmaceutiques contenant un inhibiteur de cox-ii et un relaxant musculaire
SG146637A1 (en) Tlr7 ligands for the treatment of hepatitis c
PL365985A1 (en) 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions
IL185345A0 (en) Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU3898700A (en) Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
MY138227A (en) Valdecoxib compositions
AU2003239393A1 (en) Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
EP0957925A4 (fr) Traitement de l'arthrose par administration de poly-n-acetyl-d-glucosamine
CA2433833A1 (fr) Utilisation de flumazenil dans l'elaboration d'un medicament visant a traiter la dependence a l'alcool
WO2001074365A3 (fr) Posologie efficace de galantamine reduisant les effets secondaires
EP1352657A4 (fr) Agents therapeutiques de potentialisation d'effet a base d'interferon
WO2001062263A3 (fr) Traitement du syndrome de la douleur pelvienne chronique chez l'homme
WO2001074364A3 (fr) Utilisation de galantamine dans le traitement de la maladie d'alzheimer ciblant la cause fondamentale de la maladie
WO2002026258A3 (fr) Traitement des maladies d'origine immunologique au moyen de l'administration par voie orale de fractions de plasma enrichies en immunoglobuline g
King AZT delta study: major European/Australian study finds combinations better than AZT alone
WO2002076405A3 (fr) Compositions et methodes de traitement de maladies ulceratives, de brulures, et d'etats associes
MD1610F1 (en) Method of the recidivating chronic aphthous stomatitis treatment
Gold Oral ganciclovir approved
RU2004109786A (ru) Способ лечения нарушений мнестических функций
RU2001133167A (ru) Способ лечения постишемических нарушений функций головного мозга
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP